14 Sep Myeloid Therapeutics
Robert Hofmeister, Ph.D., Chief Scientific Officer
Oct. 7 | 9:15am | FLW Ballroom G
Cambridge, MA
(Private)
At Myeloid, we have applied our extensive knowledge of advanced gene and cell therapies to build novel platform technologies that harness the innate abilities of myeloid cells. We have translated the learnings from our backgrounds and novel platform to create a clinical-stage, mRNA-immunotherapy pipeline focused on breakthrough therapies for cancer.